Endometrial cancer is a common gynecological cancer with annually increasing incidence worldwide. However, the biomarkers that provide prognosis and progression for this disease remain elusive. Two eligible human endometrial cancer datasets (GSE17025 and GSE25405) were selected for the study. A total of 520 differentially expressed mRNAs and 30 differentially expressed miRNAs were identified. These mRNAs were mainly enriched in cell cycle, skeletal system development, vasculature development, oocyte maturation, and oocyte meiosis signalling pathways. A total of 160 pairs of differentially expressed miRNAs and mRNAs, including 22 differentially expressed miRNAs and 71 overlapping differentially expressed mRNAs, were validated in endometrial cancer samples using starBase v2.0 project. The prognosis analysis revealed that Cyclin E1 (CCNE1, one of the 82 hub genes, which correlated with hsa-miR-195 and hsa-miR-424) was significantly linked to a worse overall survival in endometrial cancer patients. The hub genes and differentially expressed miRNAs identified in this study might be used as prognostic biomarkers for endometrial cancer and molecular targets for its treatment.

中文翻译：

---

子宫内膜癌候选生物标志物的生物信息学筛选及其预后价值。

子宫内膜癌是一种常见的妇科癌症，在世界范围内发病率逐年增加。但是，提供该疾病的预后和进展的生物标志物仍然难以捉摸。选择了两个合格的人子宫内膜癌数据集（GSE17025和GSE25405）进行研究。总共鉴定了520个差异表达的mRNA和30个差异表达的miRNA。这些mRNA主要富集于细胞周期，骨骼系统发育，脉管系统发育，卵母细胞成熟和卵母细胞减数分裂信号通路。使用starBase v2.0项目在子宫内膜癌样本中验证了总共160对差异表达的miRNA和mRNA，包括22个差异表达的miRNA和71个重叠的差异表达mRNA。预后分析显示，Cyclin E1（CCNE1，与hsa-miR-195和hsa-miR-424相关的82个集线器基因之一与子宫内膜癌患者较差的总体生存率显着相关。在这项研究中确定的中枢基因和差异表达的miRNA可用作子宫内膜癌的预后生物标志物和用于治疗的分子靶标。